Wednesday, October 21, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· July 6, 2026

Bank of America resets Nike stock target on recovery plan

View original at finance.yahoo.com
Bank of America resets Nike stock target on recovery plan Nike's turnaround is showing signs of progress, but not enough for Wall Street to call it a clean comeback…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Nike's fourth quarter 2026 results were in line with expectations, but the bigger change was the company's weaker sales outlook

    60% confidence

  • Hutchinson lowered the price target because Nike's sales recovery is taking longer than expected

    60% confidence

  • Earnings expectations remain largely intact because gross-margin expansion is expected to begin in the first quarter, earlier than previously expected, and because Nike is using cost controls to protect profit

    60% confidence

  • BofA kept its fiscal 2027 earnings estimate at $1.60 a share, saying lower sales should be offset by cost control and stronger gross margin

    60% confidence

  • Nike's latest earnings summed up as a 'Choppy recovery'

    60% confidence

  • BofA raised its fiscal 2028 earnings estimate to $2.13 from $2.00, reflecting lower selling, general, and administrative expenses

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,406 source documents archived
Query this data → isubstrate.com